Table 1.
Baseline characteristics of the included studies.
| First author (year) | Country | Subtype of nAMD | Sample size | Male (%) | Age (year) | Vision criteria for recruitment | Anti-VEGF use | Study design |
|---|---|---|---|---|---|---|---|---|
| Lai et al. (2007) [13] | China | Type 3 | 4 | 25.00 | 81.0 ± 4.12 | NA | Ranibizumab | Case report |
| Brown et al. (2009) [14] | America | Type 2 | 280 | 52.86 | 76.7 ± 8.08 | NA | Ranibizuma | RCT |
| Costagliola et al. (2010) [15] | Italy | Type 2 | 45 | 44.44 | 65.3 ± 15 | NA | Bevacizumab | RCT |
| Malgorzata and Stankiewicz (2011) [16] | Poland | Type 2 | 25 | 44.00 | 73.23 ± 8.55 | 22–76 ETDRS letters | Ranibizumab | Clinical trial |
| Coscas et al. (2012) [17] | France | Type 2 | 29 | 34.48 | 76.3 ± 10.9 | 20/400–20/40 by the ETDRS charts | Ranibizumab | RIS |
| Kramann et al. (2012) [18] | Germany | Type 3 | 26 | 30.77 | 77 ± 8.25 | NA | Ranibizumab | Retrospective case Series |
| Ying et al. (2013) [19] | America | Type 1, type 2, type 3 | 1105 | 38 | 79 ± 8 | 20/25–20/320 on electronic VA testing | Ranibizumab or bevacizumab | RCT |
| Shin and Yu (2014) [20] | South Korea | Type 3 | 31 | 19.35 | 70.4 ± 6.5 | 5–75 ETDRS letters (Snellen 20/32–20/800) | Ranibizumab | Clinical trial |
| Hata et al. (2015) [21] | Japan | Type 1 (PCV) | 70 | 81.43 | 72.2 ± 8.8 | 0.7 or less on a Landolt chart | Ranibizumab | RIS |
| Kano et al. (2015) [22] | Japan | Type 1 | 100 | 86 | 75.71 ± 7.79 | 0.05 or better by the Japanese decimal VA chart | Ranibizumab or aflibercept | RIS |
| Park and Roh (2015) [23] | South Korea | Type 3 | 40 | 39.02 | 67.09 ± 11.76 | NA | Ranibizumab | RIS |
| Castro-Navarro et al. (2016) [24] | Spain | Type 3 | 7 | 14.29 | 79.42 ± 7.14 | <0.1 logMAR | Aflibercept | RIS |
| Chen et al. (2016) [25] | America | Type 1, type 3 | 36 | 36.11 | 80 ± 8.0 | 19–73 ETDRS letters (Snellen 20/35–20/400) | Aflibercept | Clinical trial |
| Daniel et al. (2016) [26] | America | Type 3 | 126 | 30.95 | 81.7 ± 7.30 | 20/25–20/320 | Ranibizumab or bevacizumab | Clinical trial |
| Koizumi et al. (2016) [27] | Japan | Type 1 (PCV) | 86 | NA | NA | NA | Aflibercept | RIS |
| Lee et al. (2016) [28] | South Korea | Type 1, type 2 | 23 | 60.87 | 66.52 ± 9.28 | NA | Ranibizumab | RIS |
| Chevreaud et al. (2017) [29] | France | Type 1, PCV, type 2, type 3 | 109 | 33.03 | 76.9 ± 8.3 | NA | Ranibizumab | RIS |
| Kikushima et al. (2017) [30] | Japan | Type 1 (PCV) | 69 | 83.9 | 72.9 ± 7.9 | Decimal BCVA ≤ 1.2 in the Landolt chart | Aflibercept | RIS |
| Koh et al. (2017) [31] | Singapore | Type 1 (PCV) | 154 | 75.3 | 68.2 ± 9.0 | 78–24 ETDRS letters (Snellen 20/32–20/320) | Ranibizumab | RCT |
| Miere et al. (2017) [32] | Italy | Type 3 | 15 | 33.33 | 82.3 ± 4.9 | NA | Ranibizumab or bevacizumab | RIS |
| Saito et al. (2017) [33] | Japan | Type 1 (PCV) | 20 | 90.00 | 72.2 ± 6.4 | NA | Aflibercept | Clinical trial |
| Gharbiya et al. (2018) [34] | Italy | Type 1, type 2, type 3 | 76 | 34.21 | 78.67 ± 8.04 | NA | Ranibizumab or aflibercept | Clinical trial |
| Matsumoto et al. (2018) [35] | Japan | Type 1 (half with PCV) | 60 | 85.00 | 75.1 ± 1.0 | NA | Aflibercept | RIS |
| Mimura et al. (2018) [36] | Japan | Type 1 (PCV), type 3 | 58 | 65.52 | 73.08 | NA | Aflibercept | RIS |
†Data are mean ± standard deviation or mean. ‡nAMD: neovascular age-related macular degeneration; anti-VEGF: antivascular endothelial growth factor; PCV: polypoidal choroidal vasculopathy; NA: not available; ETDRS: Early Treatment of Diabetic Retinopathy Study; RCT: randomized controlled trial; RIS: retrospective interventional study.